TY - JOUR
T1 - Intermediate Strengths and Inflated Prices
T2 - The Story of Transdermal Fentanyl Patches
AU - Hussaini, S. M.Qasim
AU - Sedhom, Ramy
AU - Dusetzina, Stacie B.
AU - Gupta, Arjun
N1 - Publisher Copyright:
© Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - In 2015, Mylan pharmaceuticals received final approval from the Food and Drug Administration for its Supplemental Abbreviated New Drug Application and introduced three new intermediate strengths of transdermal fentanyl patches to the U.S. drug market.1 With this approval, Mylan added 37.5 , 62.5, and 87.5 mcg/hr strength patches to existing 12, 25, 50, 75, and 100 mcg/hr strength patches. Today, these intermediate strength patches cost many times more than older strengths. In this commentary, we discuss the clinical implications of intermediate strengths of the fentanyl patch, explore mechanisms for price differences, and offer practice-based and policy solutions to address these differences.
AB - In 2015, Mylan pharmaceuticals received final approval from the Food and Drug Administration for its Supplemental Abbreviated New Drug Application and introduced three new intermediate strengths of transdermal fentanyl patches to the U.S. drug market.1 With this approval, Mylan added 37.5 , 62.5, and 87.5 mcg/hr strength patches to existing 12, 25, 50, 75, and 100 mcg/hr strength patches. Today, these intermediate strength patches cost many times more than older strengths. In this commentary, we discuss the clinical implications of intermediate strengths of the fentanyl patch, explore mechanisms for price differences, and offer practice-based and policy solutions to address these differences.
KW - cancer
KW - fentanyl
KW - financial toxicity
KW - pain
KW - policy
UR - https://www.scopus.com/pages/publications/85137745537
UR - https://www.scopus.com/pages/publications/85137745537#tab=citedBy
U2 - 10.1089/jpm.2022.0241
DO - 10.1089/jpm.2022.0241
M3 - Article
C2 - 35763285
AN - SCOPUS:85137745537
SN - 1096-6218
VL - 25
SP - 1335
EP - 1337
JO - Journal of palliative medicine
JF - Journal of palliative medicine
IS - 9
ER -
